BillionToOne, Inc.
NASDAQ:BLLNMedical - Diagnostics & Research
+$0.84 today
- Market cap
- $4.37B
- Beta
- 0.90
- P/E (TTM)
- 182.6
- EPS (TTM)
- $0.55
Volume 1.44M
Average 0.59M
BLLN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
BillionToOne, Inc.NASDAQ: BLLN
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue grows in line with its trailing trend
Q2 FY2026 cost of revenue of $32.34M rose 40.0% year over year, in line with the +39.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 10.4% from the prior quarter.
Context
- Cost of revenue amounted to 31.7% of revenue in FY2025, down 15.3 pp from a year earlier.
- Cost of revenue increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth of +40.0% holds above the trailing-twelve-month pace of +39.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 96.65M USD
- Year-over-year change
- +34.9%
- 2-year CAGR
- +33.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 96.65M | +34.9% |
| FY2024 | 2024-12-31 | 71.67M | +31.7% |
| FY2023 | 2023-12-31 | 54.42M | — |
Cost of Revenue vs competitors
How BLLN compares with its peers on the latest reported figures
- BLLN's LTM Jun 2026 cost of revenue of $114.19M is the lowest of the 9 companies compared; the peer median is $222.66M.
- Its year-over-year change of +39.8% is the highest of 9, against a peer median of +11.4%.
- Cost of revenue amounts to 28.7% of revenue for BLLN, versus a peer median of 34.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $939.25M | +28.9% | +21.1% | 34.7% | |
| LTM Sep 2026 | $445.18M | +36.1% | +30.7% | 34.8% | |
| LTM Jun 2026 | $437.4M | +13.2% | +11.4% | 57.1% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Mar 2026 | $196.33M | +9.7% | -8.7% | 61.3% | |
| LTM Jun 2026 | $183.16M | -12.9% | +6.8% | 110.8% | |
| LTM Jun 2026 | $156.8M | +3.1% | +15.6% | 27.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $144.53M | +21.5% | -20.9% | 31.8% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $114.19M | +39.8% | — | 28.7% |
| Peer median (excluding BLLN) | $222.66M | +11.4% | +9.2% | 34.8% | |
Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 71.73M | 152.58M | 305.11M |
| Cost of Revenue | 54.42M | 71.67M | 96.65M |
| Gross Profit | 17.31M | 80.92M | 208.46M |
| Gross Margin | 24.1% | 53.0% | 68.3% |
| Research & Development | 22.41M | 36.6M | 49.38M |
| Selling, General & Admin | 64.39M | 91.47M | 143.05M |
| Operating Expenses | 86.8M | 128.06M | 192.44M |
| Depreciation & Amortization | 6.46M | 11.69M | 11.91M |
| EBITDA | (72.94M) | (27.47M) | 19.76M |
| EBITDA Margin | -101.7% | -18.0% | 6.5% |
| Operating Income | (69.5M) | (47.15M) | 16.02M |
| Operating Margin | -96.9% | -30.9% | 5.3% |
| Interest Income | 3.46M | 5.82M | 7.75M |
| Interest Expense | 3.27M | 2.39M | 95K |
| Other Income / Expenses | (13.18M) | 5.61M | (8.26M) |
| Income Before Tax | (82.67M) | (41.54M) | 7.76M |
| Pre-Tax Margin | -115.3% | -27.2% | 2.5% |
| Income Tax Expense | 9K | 29K | 305K |
| Net Income | (82.68M) | (41.57M) | 7.45M |
| Net Margin | -115.3% | -27.2% | 2.4% |
| EPS (Basic) | (1.85) | (0.93) | 0.06 |
| EPS (Diluted) | (1.85) | (0.93) | 0.06 |
| Weighted Avg Shares | 44.72M | 44.72M | 45.8M |
| Weighted Avg Shares (Diluted) | 44.72M | 44.72M | 45.8M |
BillionToOne, Inc.
NASDAQ:BLLN
Intrinsic Alpha fair value
Locked
Current Price
$91.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.